Halozyme Therapeutics, Inc. (LON:0J2O)
56.72
-0.99 (-1.71%)
At close: Jul 15, 2025
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $264.86M USD in the quarter ending March 31, 2025, with 35.22% growth. This brings the company's revenue in the last twelve months to $1.08B, up 25.65% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.08B
Revenue Growth
+25.65%
P/S Ratio
6.16
Revenue / Employee
$3.10M
Employees
350
Market Cap
5.17B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Halozyme Therapeutics News
- 18 days ago - Halozyme Therapeutics Added to Russell 1000® Index - PRNewsWire
- 4 weeks ago - Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - PRNewsWire
- 4 weeks ago - Halozyme Therapeutics: The Waters Become Muddled - Seeking Alpha
- 5 weeks ago - Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
- 6 weeks ago - Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
- 7 weeks ago - Halozyme to Participate at Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - What's Driving the Market Sentiment Around Halozyme Therapeutics? - Benzinga
- 7 weeks ago - Price Over Earnings Overview: Halozyme Therapeutics - Benzinga